{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:31:43Z","timestamp":1793705503664,"version":"4.5.1"},"reference-count":0,"publisher":"World Health Organization Regional Office for the Eastern Mediterranean (WHO\/EMRO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["East Mediterr Health J."],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:p>Background: Topical nanoliposomes containing 0.4% amphotericin B (Lip-AmB 0.4%) have shown promising safety results in preclinical and phase 1 clinical trials in healthy volunteers. Aims: To evaluate safety and efficacy of Lip-AmB 0.4% in cutaneous leishmaniasis patients. Methods: Fourteen patients with a total of 84 lesions received national standard treatment of weekly intralesional meglumine antimoniate with biweekly cryotherapy, or daily intramuscular meglumine antimoniate (20 mg\/kg\/day for 14 days), and topical Lip-AmB 0.4% twice daily for 28 days. Twenty-two patients with a total of 46 lesions (7 at most) were treated with topical Lip-AmB 0.4% alone twice daily for 28 days. Thirty patients with a total of 68 lesions received national standard treatment of weekly intralesional meglumine antimoniate (to blanch around the lesion) and biweekly cryotherapy. Results: Sixty-six patients with cutaneous leishmaniasis lesions completed the study. In the safety evaluation, 2 of the 36 patients evaluated reported a tolerable burning sensation and they preferred to continue treatment. Twelve (92%) of 14 patients with 84 lesions who received national standard treatment combined with Lip-AmB 0.4% completed the study with complete cure. In 1 of the patients with 4 lesions, 1 lesion showed complete cure and 3 showed partial cure. Among 22 patients with 46 lesions who received only topical LipAmB 0.4%, 19 completed the study and 18 showed complete cure (95% efficacy). In the 30 patients who received national standard treatment alone, 33 lesions in 15 patients showed complete cure (48.5%) on day 42 follow-up. Conclusion: Lip-AmB 0.4% alone or in combination with national standard treatment is safe with high-efficacy rate and warrants further investigation during phase 3 clinical trials.<\/jats:p>","DOI":"10.26719\/emhj.22.070","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T10:05:19Z","timestamp":1664445919000},"page":"658-663","source":"Crossref","is-referenced-by-count":12,"title":["Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran"],"prefix":"10.26719","volume":"28","author":[{"given":"Ali","family":"Khamesipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Tasbihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Firooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11263","published-online":{"date-parts":[[2022,9,29]]},"container-title":["Eastern Mediterranean Health Journal"],"original-title":[],"link":[{"URL":"https:\/\/applications.emro.who.int\/EMHJ\/V28\/09\/1020-3397-2022-2809-658\u2013663-eng.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T10:05:21Z","timestamp":1664445921000},"score":1,"resource":{"primary":{"URL":"https:\/\/applications.emro.who.int\/EMHJ\/V28\/09\/1020-3397-2022-2809-658\u2013663-eng.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":0,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.26719\/emhj.22.070","relation":{},"ISSN":["1020-3397","1687-1634"],"issn-type":[{"value":"1020-3397","type":"print"},{"value":"1687-1634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}